Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands

Compounds that selectively modulate multiple targets can provide clinical benefits and are an alternative to traditional highly selective agents for unique targets. High-throughput screening (HTS) for multitarget-directed ligands (MTDLs) using approved drugs, and fragment-based drug design has becom...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jianbo Sun, Hui Zhong, Kun Wang, Na Li, Li Chen
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/f560e80bb16a4f2e99ee310b9fb009cf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!